


List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10444436/publications.pdf Version: 2024-02-01



V SAITO

#	Article	IF	CITATIONS
1	Endoscopic indications for endoscopic mucosal resection of laterally spreading tumours in the colorectum. Gut, 2006, 55, 1592-1597.	12.1	389
2	Calreticulin functions in vitro as a molecular chaperone for both glycosylated and non-glycosylated proteins. EMBO Journal, 1999, 18, 6718-6729.	7.8	233
3	Calnexin Discriminates between Protein Conformational States and Functions as a Molecular Chaperone In Vitro. Molecular Cell, 1999, 4, 331-341.	9.7	164
4	Chromoscopy During Colonoscopy. Endoscopy, 2001, 33, 1036-1041.	1.8	119
5	Non-synonymous Single Nucleotide Alterations Found in the CYP2C8 Gene Result in Reduced in Vitro Paclitaxel Metabolism Biological and Pharmaceutical Bulletin, 2001, 24, 1427-1430.	1.4	103
6	Haplotype structures of the UGT1A gene complex in a Japanese population. Pharmacogenomics Journal, 2006, 6, 63-75.	2.0	80
7	Relationship between Calnexin and BiP in Suppressing Aggregation and Promoting Refolding of Protein and Glycoprotein Substrates. Journal of Biological Chemistry, 2001, 276, 39779-39787.	3.4	56
8	Homozygous CDA*3 is a major cause of life-threatening toxicities in gemcitabine-treated Japanese cancer patients. British Journal of Cancer, 2009, 100, 870-873.	6.4	56
9	Human growth hormone-stimulated growth of human cultured lymphocytes (IM-9) and its inhibition by phorbol diesters through down-regulation of the hormone receptors. Possible involvement of phosphorylation of a 55,000 molecular weight protein associated with the receptor in the down-regulation lournal of Biological Chemistry. 1990. 265. 11320-11327.	3.4	33
10	Impact of the haplotype CYP3A4*16B harboring the Thr185Ser substitution on paclitaxel metabolism in Japanese patients with cancer. Clinical Pharmacology and Therapeutics, 2006, 80, 179-191.	4.7	31
11	Genetic Polymorphisms and Haplotypes of Major Drug Metabolizing Enzymes in East Asians and Their Comparison with Other Ethnic Populations. Current Pharmacogenomics and Personalized Medicine: the International Journal for Expert Reviews in Pharmacogenomics, 2007, 5, 49-78.	0.3	30
12	Our perspective on endoscopic resection for colorectal neoplasms. Gastroenterologie Clinique Et Biologique, 2010, 34, 367-370.	0.9	29
13	Human growth hormone-stimulated growth of human cultured lymphocytes (IM-9) and its inhibition by phorbol diesters through down-regulation of the hormone receptors. Possible involvement of phosphorylation of a 55,000 molecular weight protein associated with the receptor in the down-regulation. Journal of Biological Chemistry, 1990, 265, 11320-7.	3.4	28
14	Functional characterization of CYP3A4.16: Catalytic activities toward midazolam and carbamazepine. Xenobiotica, 2009, 39, 140-147.	1.1	27
15	Ligand-induced internalization and phosphorylation-dependent degradation of growth hormone receptor in human IM-9 cells. Molecular and Cellular Endocrinology, 1994, 106, 67-74.	3.2	21
16	Effect of an ectokinase inhibitor, K252b, on degranulation and Ca2+ signals of RBL-2H3 cells and human basophils. Journal of Immunology, 1997, 159, 964-9.	0.8	17
17	Development of a detection algorithm for statin-induced myopathy using electronic medical records. Journal of Clinical Pharmacy and Therapeutics, 2013, 38, 230-235.	1.5	16
18	Activation of protein kinase Cα enhances human growth hormone-binding protein release. Molecular and Cellular Endocrinology, 1998, 146, 197-205.	3.2	14

Υ SAITO

#	Article	IF	CITATIONS
19	Release of a Soluble Form of Growth Hormone Receptors (Growth Hormone-Binding Proteins) from Human IM-9 Cells by Proteolytic Cleavage1. Journal of Biochemistry, 1995, 118, 521-525.	1.7	13
20	Casein kinase II-like ectokinase activity on RBL-2H3 cells. Immunology Letters, 1999, 68, 369-374.	2.5	8
21	An algorithm for the identification of heparin-induced thrombocytopenia using a medical information database. Journal of Clinical Pharmacy and Therapeutics, 2013, 38, 423-428.	1.5	8
22	Vertical Integration of Pharmacogenetics in Population PK/PD Modeling: A Novel Information Theoretic Method. CPT: Pharmacometrics and Systems Pharmacology, 2013, 2, 1-10.	2.5	8
23	Preparation of Monoclonal Antibodies for Immunoblotting Human Growth Hormone Receptor and Growth Hormone-Binding Protein Biological and Pharmaceutical Bulletin, 1994, 17, 983-986.	1.4	7
24	Development of a novel algorithm for detecting glucocorticoid-induced diabetes mellitus using a medical information database. Journal of Clinical Pharmacy and Therapeutics, 2017, 42, 215-220.	1.5	7
25	Proteasome inhibitor enhances growth hormone-binding protein release. Molecular and Cellular Endocrinology, 2001, 182, 157-163.	3.2	6
26	Role of ecto-kinase in phorbol ester-enhanced growth hormone-binding protein release from human IM-9 cells. Molecular and Cellular Endocrinology, 1999, 152, 65-72.	3.2	5
27	Proteasomes Are Involved in the Constitutive Degradation of Growth Hormone Receptors Biological and Pharmaceutical Bulletin, 2001, 24, 744-748.	1.4	5
28	Endoscopic Submucosal Dissection of Colorectal Neoplasias – Step-by-Step Explanation, Technical Aspects. Video Journal and Encyclopedia of GI Endoscopy, 2013, 1, 348-350.	0.1	1
29	Piecemeal mucosectomy, submucosal dissection or transanal microsurgery for large colorectal neoplasm. Colorectal Disease, 2015, 17, 44-51.	1.4	1
30	CDA (Cytidine Deaminase). Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2011, , .	0.1	0
31	Assessment of Likelihood of Submucosal Invasion in Colorectal Lesions. Video Journal and Encyclopedia of GI Endoscopy, 2013, 1, 303-305.	0.1	0